Table of Contents

company-logo

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology Dividend Announcement

• Vir Biotechnology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Vir Biotechnology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Vir Biotechnology Dividend History

Vir Biotechnology Dividend Yield

Vir Biotechnology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Vir Biotechnology stock? Use our calculator to estimate your expected dividend yield:

Vir Biotechnology Financial Ratios

P/E ratio-2.53
PEG ratio-0.03
P/B ratio1.09
ROE-36.71%
Payout ratio0.00%
Current ratio8.94
Quick ratio8.98
Cash Ratio2.20

Vir Biotechnology Dividend FAQ

Does Vir Biotechnology stock pay dividends?
Vir Biotechnology does not currently pay dividends to its shareholders.
Has Vir Biotechnology ever paid a dividend?
No, Vir Biotechnology has no a history of paying dividends to its shareholders. Vir Biotechnology is not known for its dividend payments.
Why doesn't Vir Biotechnology pay dividends?
There are several potential reasons why Vir Biotechnology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Vir Biotechnology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Vir Biotechnology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Vir Biotechnology a dividend aristocrat?
Vir Biotechnology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Vir Biotechnology a dividend king?
Vir Biotechnology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Vir Biotechnology a dividend stock?
No, Vir Biotechnology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Vir Biotechnology stocks?
To buy Vir Biotechnology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Vir Biotechnology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.